Trials / Completed
CompletedNCT04288687
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer. The study enrolls participants with history of advanced prostate cancer that is growing despite standard hormonal therapies, such as androgen-deprivation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib Pill | Niraparib 200 mg by mouth daily (2 x 100 mg pills) |
Timeline
- Start date
- 2020-10-19
- Primary completion
- 2024-02-20
- Completion
- 2024-02-20
- First posted
- 2020-02-28
- Last updated
- 2026-03-04
- Results posted
- 2026-03-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04288687. Inclusion in this directory is not an endorsement.